Skip to content

Ketamine research published in 2023

Page 3 of 18: studies 41 to 60 of 355, newest first. Back to the ketamine overview

Studies

Exploring Ketamine's Repurposing for Treating Cocaine Use Disorder: A Ghanaian Perspective on Ethical and Legal Constraints

Journal of Health, Medicine and Nursing November 1, 2023 Prince Opuni Frimpong 1 citation

Ketamine, a dissociative anesthetic commonly used in medical settings, has shown promising results in treating various mental health disorders. Recent studies have suggested its potential repurposing for treating cocaine use disorder (CUD). However, before implementing such a treatment approach, it is crucial to consider the ethical and legal constraints associated with it from a Ghanaian...

Intravenous ketamine for benzodiazepine deprescription and withdrawal management in treatment-resistant depression: a preliminary report.

Neuropsychopharmacology November 1, 2023 Nicolas Garel, Kyle T. Greenway, Lê-Anh Dinh-Williams et al. 10 citations

We present the first evidence that sub-anesthetic ketamine infusions for treatment resistant depression (TRD) may facilitate deprescription of long-term benzodiazepine/z-drugs (BZDRs). Long-term BZDR prescriptions are potentially harmful yet common, partly because of challenging withdrawal symptoms. Few pharmacological interventions have evidence for facilitating BZDR discontinuation, and none...

Functional imaging studies of acute administration of classic psychedelics, ketamine, and MDMA: Methodological limitations and convergent results.

Neuroscience & Biobehavioral Reviews November 1, 2023 Sophia Linguiti, Jacob W Vogel, Valerie J Sydnor et al. 15 citations

Functional magnetic resonance imaging (fMRI) is increasingly used to non-invasively study the acute impact of psychedelics on the human brain. While fMRI is a promising tool for measuring brain function in response to psychedelics, it also has known methodological challenges. We conducted a systematic review of fMRI studies examining acute responses to experimentally administered psychedelics...

Indirect adjusted comparison of 6-month clinical outcomes between esketamine nasal spray and other real-world polypharmacy treatment strategies for treatment resistant depression: results from the ICEBERG study

Frontiers in Psychiatry October 31, 2023 Albino J Oliveira-Maia, Benoit Rive, Joachim Morrens et al. 6 citations

BackgroundThe efficacy of esketamine nasal spray (NS) as a rapid-acting agent for treatment resistant depression (TRD) was demonstrated in comparisons with placebo, when both were given in addition to a newly initiated selective serotonin reuptake inhibitor (SSRI)/serotonin norepinephrine reuptake inhibitor (SNRI). How esketamine NS compares with commonly used real-world (RW) polypharmacy...

DOI: 10.3389/fpsyt.2023.1250987 (opens in new tab) Full text (opens in new tab) Esketamine nasal spray Treatment resistant depression Real-world evidence Indirect comparison +2

Ketamine retards recovery from reward downshift and supports conditioned taste aversion.

Pharmacology, Biochemistry, and Behavior October 28, 2023 Antonio D R Agüera, Clara Cándido, Rocío Donaire et al. 4 citations

Ketamine is a noncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist with antidepressant, anxiolytic, and memory effects in clinical and preclinical studies. The present studies investigated the behavioral effects of ketamine in animals exposed to a consummatory successive negative contrast (cSNC) task involving unexpected reward downshift, negative emotion (frustration), and aversive...

DOI: 10.1016/j.pbb.2023.173671 (opens in new tab) Full text (opens in new tab) Conditioned taste aversion Frustration Motivational summation Reward downshift +5

Transcranial magnetic stimulation and ketamine: implications for combined treatment in depression

Frontiers in Neuroscience October 26, 2023 Weronika Dębowska, Magdalena Więdłocha, Marta Dębowska et al.

Drug-resistant mental disorders, particularly treatment-resistant depression, pose a significant medical and social problem. To address this challenge, modern psychiatry is constantly exploring the use of novel treatment methods, including biological treatments, such as transcranial magnetic stimulation (TMS), and novel rapid-acting antidepressants, such as ketamine. While both TMS and ketamine...

Case report: Maintaining altered states of consciousness over repeated ketamine infusions may be key to facilitate long-lasting antidepressant effects: some initial lessons from a personalized-dosing single-case study.

Frontiers in Psychiatry October 25, 2023 Steffen Reissmann, Matthias Hartmann, Andreas Kist et al.

Background: The interest in psychoactive agents for treating mental disorders has gathered a growing body of scientific interest. However, research on the relationship between altered states of consciousness (ASCs) and ketamine's antidepressant properties is still limited. Likewise, approaches to sustain early treatment success for the long-term are needed. Taking both aspects into account, the...

Aromatase inhibition and ketamine in rats: sex-differences in antidepressant-like efficacy

Biology of Sex Differences October 24, 2023 Sandra Ledesma-Corvi, Jordi Jornet-Plaza, M. García-Fuster

Ketamine is a novel fast-acting antidepressant recently approved for treatment-resistant depression. Since preclinical studies showed sex differences in its efficacy, probably driven by sex hormones (estrogens and testosterone), we evaluated the antidepressant-like effects of ketamine in male and female rats when the biosynthesis of estrogens was inhibited. To do so, we utilized letrozole, an...

Ketamine’s acute effects on negative brain states are mediated through distinct altered states of consciousness in humans

Nature Communications October 19, 2023 Laura M Hack, Xue Zhang, Boris D. Heifets et al. 20 citations

Ketamine commonly and rapidly induces dissociative and other altered states of consciousness (ASCs) in humans. However, the neural mechanisms that contribute to these experiences remain unknown. We used functional neuroimaging to engage key regions of the brain’s affective circuits during acute ketamine-induced ASCs within a randomized, multi-modal, placebo-controlled design examining placebo,...

Randomized trial of ketamine masked by surgical anesthesia in patients with depression

Nature Mental Health October 19, 2023 Theresa R. Lii, Ashleigh E. Smith, Josephine R. Flohr et al. 94 citations

Ketamine may have antidepressant properties, but its acute psychoactive effects complicate successful masking in placebo-controlled trials. Here we present a single-center, parallel-arm, triple-masked, randomized, placebo-controlled trial assessing the antidepressant efficacy of intravenous ketamine masked by surgical anesthesia (ClinicalTrials.gov, NCT03861988). Adult patients (N = 40) with...

Intranasal esketamine as tool for rapid cycling bipolar disorder: A case report of successful mood stabilization

Psychiatry Research Case Reports October 18, 2023 Giacomo D’andrea, Ornella di Marco, Francesco Maria Semeraro et al. 1 citation

Rapid Cyclic Bipolar Disorder (RCBD) is a debilitating condition that manifests as four or more episodes of depression, mania, or hypomania in a span of one year, with depression being the predominant event. RCBD is prevalent among individuals diagnosed with bipolar disorder and is associated with elevated suicide risk, prolonged disease duration, unfavorable clinical outcomes, and cognitive...

DOI: 10.1016/j.psycr.2023.100188 (opens in new tab) Major depressive disorder Hypomania Bipolar disorder Context archaeology +4

Sustained antidepressant effect of ketamine through NMDAR trapping in the LHb

Nature October 18, 2023 Shuangshuang Ma, Min Chen, Yihao Jiang et al. 202 citations

The discrepancy between the short half-life of ketamine and its long-lasting effects is due to ketamine being trapped in NMDA receptors, and its release depends on neural activity in the lateral habenula. Ketamine, an N -methyl- d -aspartate receptor (NMDAR) antagonist^ 1 , has revolutionized the treatment of depression because of its potent, rapid and sustained antidepressant effects^ 2 – 4 ....

Temporal dynamics of BDNF signaling recruitment in the rat prefrontal cortex and hippocampus following a single infusion of a translational dose of ketamine

Neuropharmacology October 17, 2023 Lucia Caffino, Francesca Mottarlini, Alessandro Piva et al. 14 citations

Despite several decades of investigations, the mechanisms underlying the rapid action of ketamine as antidepressant are still far from being completely understood. Several studies indicated Brain-Derived Neurotrophic Factor (BDNF) as critical for the fast antidepressant action of ketamine, due to its contribution in early and rapid synaptic adaptations. However, previous reports have been...

Resolution of stuttering during ketamine treatment: a case report

Journal of Medical Case Reports October 15, 2023 Dan Bolton, Tegest Hailu, Christina A. Porucznik 2 citations

Abstract Background Stuttering may include repetition of words in whole or part, difficulty saying words, and elongated pauses in speech. Approximately 5% of children stutter for a period lasting 6 months or more. Most of those children stop stuttering as they approach adulthood, but the condition persists in approximately 1% of adults. The cause of stuttering is unknown. Adults who stutter...

Multidisciplinary development of guidelines for ketamine treatment for treatment-resistant major depression disorder for use by adult specialist mental health services in New Zealand

BJPsych Open October 13, 2023 Ben Beaglehole, Paul Glue, Mike Clarke et al. 9 citations

Background The evidence base for racemic ketamine treatment for treatment-resistant major depressive disorder (TRD) continues to expand, but there are major challenges translating this evidence base into routine clinical care. Aim To prepare guidelines for ketamine treatment of TRD that are suitable for routine use by publicly funded specialist mental health services. Method We consulted with...

Repurposing of recreational drugs: will these new ‘medicines’ (e.g., psychedelics, psilocybin, cannabinoids, LSD, MDMA, ketamine) deliver short- or longer-term benefits for those with depressive or other mood disorders?

Research Directions Depression October 13, 2023 Ian B. Hickie, F. Markus Leweke, Allan H. Young 1 citation

In recent years, there has been considerable enthusiasm among research groups focused on developing novel therapies for treatment-resistant depression, and a wider community that has had experiences using recreational drugs, in more systematic evaluation of the therapeutic value of these compounds (Goodwin et al., 2022; Young, 2023). This has also been associated with advocacy for...

Effects of NMDA-receptor blockade by ketamine on mentalizing and its neural correlates in humans: a randomized control trial

Scientific Reports October 11, 2023 Sven Wasserthal, Mirko Lehmann, Claudia Neumann et al. 7 citations

Schizophrenia is associated with various deficits in social cognition that remain relatively unaltered by antipsychotic treatment. While faulty glutamate signaling has been associated with general cognitive deficits as well as negative symptoms of schizophrenia, no direct link between manipulation of glutamate signaling and deficits in mentalizing has been demonstrated thus far. Here, we...

Hippocampal subfield volumes in treatment resistant depression and serial ketamine treatment

Frontiers in Psychiatry October 9, 2023 Artemis Zavaliangos-Petropulu, Shawn M. Mcclintock, S. Joshi et al. 6 citations

Introduction Subanesthetic ketamine is a rapidly acting antidepressant that has also been found to improve neurocognitive performance in adult patients with treatment resistant depression (TRD). Provisional evidence suggests that ketamine may induce change in hippocampal volume and that larger pre-treatment volumes might be related to positive clinical outcomes. Here, we examine the effects of...

Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression

New England Journal of Medicine October 4, 2023 Andreas Reif, Istvan Bitter, Jozefien Buyze et al. 197 citations

BACKGROUND: In treatment-resistant depression, commonly defined as a lack of response to two or more consecutive treatments during the current depressive episode, the percentage of patients with remission is low and the percentage with relapse is high. The efficacy and safety of esketamine nasal spray as compared with extended-release quetiapine augmentation therapy, both in combination with...

The endogenous opioid system in the medial prefrontal cortex mediates ketamine’s antidepressant-like actions

Research Square October 3, 2023 Christopher Pittenger, Cheng Jiang, Ralph Dileone et al. preprint

Recent studies have implicated the endogenous opioid system in the antidepressant actions of ketamine, but the underlying mechanisms remain unclear. We used a combination of pharmacological, behavioral, and molecular approaches in rats to test the contribution of the prefrontal endogenous opioid system to the antidepressant-like effects of a single dose of ketamine. Both the behavioral actions...